Previous close | 4.4700 |
Open | N/A |
Bid | 2.3000 |
Ask | 6.0000 |
Strike | 35.00 |
Expiry date | 2025-01-17 |
Day's range | 4.4700 - 4.4700 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL on Monday, June 10, 2024, at 9:20 a.m. ET.
Investors in Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) had a good week, as its shares rose 7.7% to close at...